Table 2. Mean change from baseline in the IIEF domain score.
| IIEF domains | Placebo (n = 39) | Avanafil 50 mg (n = 40) | Avanafil 100 mg (n = 40) | Avanafil 200 mg (n = 39) | |
|---|---|---|---|---|---|
| EF | Responses (8 wk) | 18.6 (7.6) | 20.7 (5.5) | 22.6 (5.9) | 25.3 (4.1) |
| Change from baseline | 3.2 (1.4, 5.1) | 4.9 (3.1, 6.7) | 6.8 (5.0, 8.6)† | 9.1 (7.3, 11.0)† | |
| Intercourse satisfaction | Responses (8 wk) | 8.5 (2.8) | 9.3 (2.3) | 9.8 (3.3) | 11.2 (2.9) |
| Change from baseline | 2.4 (1.5, 3.3) | 3.0 (2.2, 3.9) | 3.4 (2.5, 4.2) | 4.9 (4.0, 5.8)† | |
| Orgasmic function | Responses (8 wk) | 5.8 (2.8) | 6.8 (2.4) | 7.3 (2.4) | 8.4 (1.7) |
| Change from baseline | 0.7 (−0.03, 1.5) | 1.7 (1.0, 2.5) | 2.1 (1.3, 2.8)* | 3.1 (2.3, 3.8)† | |
| Sexual desire | Responses (8 wk) | 5.8 (2.0) | 6.6 (1.6) | 6.9 (2.0) | 7.6 (1.6) |
| Change from baseline | 0.9 (0.3, 1.4) | 1.4 (0.8, 1.9) | 1.4 (0.9, 1.9) | 2.1 (1.5, 2.6)* | |
| Overall satisfaction | Responses (8 wk) | 5.3 (2.2) | 5.9 (1.8) | 6.1 (2.3) | 7.4 (1.7) |
| Change from baseline | 1.0 (0.3, 1.6) | 1.6 (1.0, 2.2) | 1.8 (1.2, 2.5) | 3.1 (2.4, 3.7)† | |
| Question 3 | Responses (8 wk) | 3.4 (1.5) | 4.1 (1.2) | 4.3 (1.0) | 4.8 (0.5) |
| Change from baseline | 0.2 (−0.1, 0.5) | 0.8 (0.5, 1.2)* | 1.0 (0.7, 1.3)* | 1.4 (1.0, 1.7)† | |
| Question 4 | Responses (8 wk) | 2.7 (1.5) | 2.6 (1.4) | 3.1 (1.6) | 3.7 (1.3) |
| Change from baseline | 1.1 (0.7, 1.6) | 1.1 (0.6, 1.5) | 1.5 (1.0, 1.9) | 2.1 (1.6, 2.6)* |
All values are expressed as mean (SD) and number (95% CI).
EF = erectile function, IIEF = International Index of Erectile Function, SD = standard deviation, CI = confidence interval.
*P < 0.05; †P < 0.001, vs. placebo.